Latest Breaking News On - Sternir inc - Page 1 : comparemela.com

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ETBOSTON and ATLANTA, May 15, 2024 Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing.

United statesAlex loboMiltonh wernerOffice of cardiologyDivision of cardiologySternir incCompany contactSteam reviewExchange commissionInhibikase or companyDivision of hematologic malignanciesInhibikase therapeutics incAbelson tyrosine kinasesChief executive officerUpcoming milestonesMeeting minutes

Inhibikase Therapeutics Reports First Quarter Financial

Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET.

United statesMiltonh wernerAlex loboInhibikase therapeutics incDivision of hematologic malignanciesInhibikase or companyExchange commissionSteam reviewCompany contactDivision of cardiologySternir incOffice of cardiologyAbelson tyrosine kinasesChief executive officerUpcoming milestonesMeeting minutes

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

BOSTON and ATLANTA, April 18, 2024 Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson s.

United statesMiltonh wernerAlex loboInhibikase or companySternir incExchange commissionInstitute of the national institutes healthNational institute of neurological diseaseCompany contactDrug administration for ikInhibikase therapeutics incAbelson tyrosine kinasesFellow shareholdersInhibikase therapeuticsDrug administrationMultiple system atrophy

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesMiltonh wernerAlex loboCompany contactInhibikase therapeutics incInstitute of the national institutes healthInhibikase or companyNational institute of neurological diseaseSternir incDrug administration for ikDevelopment programsExchange commissionTherapeutics issues letterProvides updateAbelson tyrosine kinasesFellow shareholders

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

BOSTON and ATLANTA, Dec. 19, 2023 (GLOBE NEWSWIRE) Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage phar.

United statesAlex loboMiltonh wernerCompany contactInhibikase therapeutics incInhibikase or companyEuropean unionSternir incExchange commissionAbelson tyrosine kinasesFellow shareholdersInhibikase therapeuticsMultiple system atrophyOrphan drug designationAbelson tyrosine kinaseAbleson tyrosine